KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Payables: 2018-2025

Historic Payables for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $132.4 million.

  • Esperion Therapeutics' Payables rose 279.69% to $132.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 246.73%. This contributed to the annual value of $106.2 million for FY2024, which is 234.90% up from last year.
  • As of Q3 2025, Esperion Therapeutics' Payables stood at $132.4 million, which was up 2.24% from $129.5 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Payables high stood at $132.4 million for Q3 2025, and its period low was $12.8 million during Q2 2022.
  • For the 3-year period, Esperion Therapeutics' Payables averaged around $64.1 million, with its median value being $34.9 million (2024).
  • As far as peak fluctuations go, Esperion Therapeutics' Payables crashed by 66.22% in 2021, and later spiked by 345.48% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Payables (Quarterly) stood at $17.6 million in 2021, then surged by 31.21% to $23.0 million in 2022, then soared by 37.66% to $31.7 million in 2023, then surged by 234.90% to $106.2 million in 2024, then soared by 279.69% to $132.4 million in 2025.
  • Its Payables was $132.4 million in Q3 2025, compared to $129.5 million in Q2 2025 and $126.7 million in Q1 2025.